Literature DB >> 1649852

Disturbed secretion of atrial natriuretic peptide in patients with persistent atrial standstill: endocrinologic silence.

Y Seino1, S Shimai, C Ibuki, K Itoh, T Takano, H Hayakawa.   

Abstract

Persistent atrial standstill is a very rare pathophysiologic condition whose diagnosis is established when both electrical and mechanical silence of the atria are confirmed. To test the hypothesis that secretion of atrial natriuretic peptide is disturbed in patients with persistent atrial standstill, the response of atrial natriuretic peptide secretion and other neurohormonal factors during exercise was investigated in three patients with a rate-responsive ventricular demand (VVI) pacemaker implanted for confirmed persistent atrial standstill. The results were compared with those observed in eight normal subjects and patients with a rate-responsive VVI (Group A) or atrial demand (AAI) (Group B) pacemaker implanted for confirmed sick sinus syndrome. Patients in Group A displayed significant elevation of alpha-human atrial natriuretic peptide secretion both before and during exercise (122.5 +/- 14.8 and 207.5 +/- 8.3 pg/ml, respectively) compared with those in Group B (55 +/- 14.1 and 116.4 +/- 51.5 pg/ml, respectively) and the normal subjects (18.9 +/- 9.8 and 30.8 +/- 19.2 pg/ml, respectively). This indicated development of a nonphysiologic increase in atrial volume or pressure overload, or both, in rate-responsive VVI pacing because of lack of atrioventricular synchrony. However, patients with persistent atrial standstill had undetectable (less than 10 pg/ml) or almost undetectable secretion of atrial natriuretic peptide as well as lower levels of cyclic guanosine monophosphate in the circulation both before and during exercise. Changes in plasma catecholamines during exercise were similar in patients with persistent atrial standstill compared with the other groups. This study indicates that "endocrinologic silence" accompanies electrical and mechanical silence of the atria, which may constitute a third diagnostic clue to persistent atrial standstill.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649852     DOI: 10.1016/0735-1097(91)90601-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

Review 1.  Neuroendocrine changes in chronic cardiac failure.

Authors:  D P Nicholls; G N Onuoha; G McDowell; J S Elborn; M S Riley; A M Nugent; I C Steele; C Shaw; K D Buchanan
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

Review 2.  Heart failure and atrial fibrillation: current concepts and controversies.

Authors:  M P Van den Berg; A E Tuinenburg; H J Crijns; I C Van Gelder; A T Gosselink; K I Lie
Journal:  Heart       Date:  1997-04       Impact factor: 5.994

3.  Usefulness of the brain natriuretic peptide to atrial natriuretic peptide ratio in determining the severity of mitral regurgitation.

Authors:  Ken Shimamoto; Miyako Kusumoto; Rieko Sakai; Hirota Watanabe; Syunichi Ihara; Natsuka Koike; Masatoshi Kawana
Journal:  Can J Cardiol       Date:  2007-03-15       Impact factor: 5.223

4.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

5.  Determinants of submaximal exercise capacity in patients at risk for heart failure with preserved ejection fraction-results from the DIAST-CHF study.

Authors:  Raoul Stahrenberg; André Duvinage; Meinhard Mende; Götz Gelbrich; Wiebke Auf der Heide; Hans-Dirk Düngen; Lutz Binder; Kathleen Nolte; Christoph Herrmann-Lingen; Gerd Hasenfuß; Burkert Pieske; Rolf Wachter; Frank Edelmann
Journal:  ESC Heart Fail       Date:  2015-04-27

Review 6.  Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation.

Authors:  Masako Baba; Kentaro Yoshida; Masaki Ieda
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

7.  Characteristics of acute congestive heart failure with normal ejection fraction and less elevated B-type natriuretic peptide.

Authors:  Ken Shimamoto; Natsuha Koike; Kiyoko Mizuochi; Miho Honma; Yufuko Kasai; Akiko Sakai; Etsuko Fujita; Masatoshi Kawana
Journal:  BMC Cardiovasc Disord       Date:  2009-01-24       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.